SEATTLE--(BUSINESS WIRE)--Nativis, Inc., a clinical stage life sciences company developing non-invasive, medical device therapies for cancers and other serious diseases, today announced that it has entered into an Evaluation Agreement with a major pharmaceutical company based in Japan. The core purpose of the Evaluation Agreement is to confirm the results of both In-Vitro and In-Vivo experiments that have been successfully completed by Nativis at independent research facilities in the United States.
The pharmaceutical company will conduct additional experiments in its labs. Both companies also plan to continue discussions around other potential business opportunities involving Nativis technologies and products in Japan.
“We are very pleased to enter into this agreement,” stated Chris Rivera, Nativis Chairman and Chief Executive Officer. “We look forward to their findings and to our ongoing conversations about other potential collaborations.”
About Nativis, Inc.
Nativis is a clinical stage bioelectronics company, based in Seattle, Washington, that develops non-invasive treatments for cancers and other serious diseases. Nativis utilizes its proprietary Radio Frequency Energy (RFE) technology which regulates defined bioactive targets by specific modulation of charge pathways. RFE modulated control of charge pathways has the potential to significantly change the way cancer and other serious diseases are treated.